A new 68Ge/68Ga generator system using an organic polymer containing N-methylglucamine groups as adsorbent for 68Ge

Chemical radioanalysis of production of positron-emitting radioisotope Gallium-68 via (p,n) and (p,2n) reactions using compact cyclotron for tomography applications

In this study, the proton-induced reactions of 68Zn and 69Ga aimed at generating 68Ga were simulated and modeled using Talys code and neural network software. In the first step, both targets were simulated under different proton energies and at different bombardments times to generate a total of six thousand data. Then, the obtained data from the Talys, including the various cross-sections, contaminations, the main product i.e. 68Ga, and other options were completely saved in the output file. Afterwards, the inputs of the neural network were selected from the output of the Talys by analyzing and considering most of the key features. A total of four inputs, two of which are different energies related to the reaction, the other is the process sequence and the fourth input is the bombardment time, were recognized as suitable inputs and the model was trained differently depending on the type of target. The selected model was a feed-forward neural network with 5 nodes in a middle layer, which was able to estimate the output of Talys code by changing the input parameters with extremely high accuracy. Two different models including the main model for estimating the output of the main sample (product) and the sub-model for estimating process pollution or impurity were trained, and then the trained model was tested on the deduced process data. The implementation results fully demonstrated the high accuracy of the method. The neural network model is much easier to implement than the Talys code, and its execution speed is very high. In addition, it can be used appropriately as a system alternative for optimization and different structures in medical and biological engineering.

[Development of Molecular Probes for Live Imaging of Cancer and Infectious Diseases]

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are powerful molecular imaging methods for examining disease-related factors in the whole body using specific imaging probes. Recently, we tried to develop molecular imaging probes that specifically visualize pathological factors associated with cancers and infectious diseases. Although survivin is highly expressed in several cancers, its expression is undetectable in non-dividing tissues. Thus, we developed several small molecular imaging probes that target survivin. These ligands not only showed high affinity for survivin protein, but also showed consistent cellular accumulation with respect to survivin expression levels, thereby indicating the feasibility of their backbones as scaffolds for tumor-specific imaging agents that target survivin. Prion diseases are fatal neurodegenerative diseases characterized by the deposition of amyloid plaques containing abnormal prion protein aggregates (PrP^Sc). Thus, we developed flavonoids, acridines, and benzofurans as PrP^Sc-imaging probes. A styrylchromone derivative ([¹²³I]SC-OMe) appears to be a particularly promising SPECT radioligand for monitoring prion deposit levels in living brains. Gallium-68 is a positron emitter in clinical PET applications that can be produced by a ⁶⁸Ge/⁶⁸Ga generator without a cyclotron. Notably, we developed new adsorbents for ⁶⁸Ge by introducing N-methylglucamine groups into the Sephadex series to serve as a hydrophilic polymer matrix. We also demonstrated that generator-eluted ⁶⁸Ga-citrate could be used for PET imaging of infectious mouse models. Our polysaccharide-based ⁶⁸Ge/⁶⁸Ga generators were shown to be prospectively cost-effective production systems for ⁶⁸Ga radiopharmaceuticals. This Review describes the major findings of these three studies and the future prospect of these fields.

Development of a 68Ge/68Ga Generator System Using Polysaccharide Polymers and Its Application in PET Imaging of Tropical Infectious Diseases

Gallium-68 (⁶⁸Ga) is a positron emitter for clinical positron emission tomography (PET) applications that can be produced by a ⁶⁸Ge/⁶⁸Ga generator without cyclotron. However, commercially available ⁶⁸Ge/⁶⁸Ga generator systems require multiple steps for the preparation of ⁶⁸Ga radiopharmaceuticals and are sometimes plagued by metallic impurities in the ⁶⁸Ga eluent. We developed a ⁶⁸Ge/⁶⁸Ga generator system using polysaccharide-based adsorbents and direct application of the generator-eluted ⁶⁸Ga-citrate to PET imaging of tropical infectious diseases. N-Methylglucamine (MG) as a ⁶⁸Ge-adsorbing unit (Sepha-MGs) was introduced to a series of Sephadex G-10, G-15, G-25, G-50, and G-75. In the batch method, over 97% of the ⁶⁸Ge in the solution was adsorbed onto the Sepha-MG series within 15 min. In particular, ⁶⁸Ge was effectively adsorbed on the Sepha(15)-MG packed columns and 70-80% of the ⁶⁸Ga was eluted by 1 mL of 0.1 M trisodium citrate with low ⁶⁸Ge contamination (<0.001%). The chemical form of the generator-eluted ⁶⁸Ga solution was identified as ⁶⁸Ga-citrate. In PET studies, affected regions in mice infected with Leishmania and severe fever with thrombocytopenia syndrome virus were clearly visualized using the ⁶⁸Ga-citrate. Sepha-MGs are useful adsorbents for ⁶⁸Ge/⁶⁸Ga generator systems with high ⁶⁸Ga elution efficiency and minimal ⁶⁸Ge breakthrough. These results indicated that eluted ⁶⁸Ga-citrate can be directly used for PET imaging of infectious sites in mice. This novel generator system may be useful for straightforward PET imaging of infection in clinical practice.

A simple method for preparation of pure 68 Ga-acetate precursor for formulation of radiopharmaceuticals: Physicochemical characteristics of the 68 Ga eluate of the SnO2 based-68 Ge/68 Ga column generator

Gallium-68 radioisotope is an excellent source in clinical positron emission tomography application due to its ease of availability from germanium-68 (⁶⁸ Ge)/gallium-68 (⁶⁸ Ga) generator having a shelf life of 1 year. In this paper, a modified method for purification of the primary eluate of ⁶⁸ Ge-⁶⁸ Ga generator by using a small cation exchange resin (Dowex-50) column has been described. The breakthrough of ⁶⁸ Ge before and after purification of ⁶⁸ Ga eluate was 0.014% and 0.00027%, respectively. The average recovery yield of ⁶⁸ Ga after purification was 84% ± 8.6% (SD, n = 335). The results of the physiochemical studies confirmed that the ⁶⁸ Ga-acetate obtained is suitable for labeling of radiopharmaceuticals.

Inorganic oxides with potential application in the preparation of a 68Ge/68Ga generator system

The ion exchange properties of some tin and titanium oxides with potential application in the development of a ⁶⁸Ge/⁶⁸Ga generator were determined. The best potential candidates, SnO₂ and calcined SnO₂, were further characterized by powder X-Ray Diffraction (XRD), Scanning Electron Microscopy (SEM) and Brunauer-Emmett-Teller (BET) surface area analysis and its radiation stability was also determined. Two ⁶⁸Ge/⁶⁸Ga pilot generators (1.85MBq) based on SnO₂ and calcined SnO₂ were developed and evaluated over 100 and 200 elution cycles respectively, using as eluent different concentrations of HCl. The generator based on calcined SnO₂ showed higher ⁶⁸Ga elution yield and lower ⁶⁸Ge content in the eluate (75-80% and <3×10^-3% respectively, 1-2M HCl) than the generator based on unheated SnO₂ (60-65% and <1×10^-1% respectively, 1-2M HCl). Nano-crystalline calcined SnO₂ proved to be a promising sorbent; therefore it should be considered as an attractive candidate to develop ⁶⁸Ge/⁶⁸Ga generators to produce gallium-68 for biomedical purposes.

Preparation of ⁶⁸Ga-labelled DOTA-peptides using a manual labelling approach for small-animal PET imaging

(68)Ga-DOTA-peptides are a promising PET radiotracers used in the detection of different tumours types due to their ability for binding specifically receptors overexpressed in these. Furthermore, (68)Ga can be produced by a (68)Ge/(68)Ga generator on site which is a very good alternative to cyclotron-based PET isotopes. Here, we describe a manual labelling approach for the synthesis of (68)Ga-labelled DOTA-peptides based on concentration and purification of the commercial (68)Ga/(68)Ga generator eluate using an anion exchange-cartridge. (68)Ga-DOTA-TATE was used to image a pheochromocytoma xenograft mouse model by a microPET/CT scanner. The method described provides satisfactory results, allowing the subsequent (68)Ga use to label DOTA-peptides. The simplicity of the method along with its implementation reduced cost, makes it useful in preclinical PET studies.

Radiosynthesis of clinical doses of ⁶⁸Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based ⁶⁸Ge/⁶⁸Ga generators

INTRODUCTION

68Ga-DOTATATE is a radiolabeled peptide-based agonist that targets somatostatin receptors overexpressed in neuroendocrine tumors. Here, we present our results on validation of organic matrix 68Ge/68Ga generators (ITG GmbH) applied for radiosynthesis of the clinical doses of 68Ga-DOTATATE (GalioMedixTM).

METHODS

The clinical grade of DOTATATE (25 μg±5 μg) compounded in 1 M NaOAc at pH=5.5 was labeled manually with 514±218 MBq (13.89±5.9 mCi) of 68Ga eluate in 0.05 N HCl at 95°C for 10 min. The radiochemical purity of the final dose was validated using radio-TLC. The quality control of clinical doses included tests of their osmolarity, endotoxin level, radionuclide identity, filter integrity, pH, sterility and 68Ge breakthrough.

RESULTS

The final dose of 272±126 MBq (7.35±3.4 mCi) of 68Ga-DOTATATE was produced with a radiochemical yield (RCY) of 99%±1%. The total time required for completion of radiolabeling and quality control averaged approximately 35 min. This resulted in delivery of 50%±7% of 68Ga-DOTATATE at the time of calibration (not decay corrected).

CONCLUSIONS

68Ga eluted from the generator was directly applied for labeling of DOTA-peptide with no additional pre-concentration or pre-purification of isotope. The low acidity of 68Ga eluate allows for facile synthesis of clinical doses with radiochemical and radionuclide purity higher than 98% and average activity of 272±126 MBq (7.3±3 mCi). There is no need for post-labeling C18 Sep-Pak purification of final doses of radiotracer. Advances in knowledge and implications for patient care. The clinical interest in validation of 68Galabeled agents has increased in the past years due to availability of generators from different vendors (Eckert-Ziegler, ITG, iThemba), favorable approach of U.S. FDA agency to initiate clinical trials, and collaboration of U.S. centers with leading EU clinical sites. The list of 68Ga-labeled tracers evaluated in clinical studies should growth because of the sensitivity of PET technique, the simplicity of the shakebake approach for the dose preparation and reliability of 68Ge/68Ga generators. Our studies have confirmed the reproducible elution profile, and high reliability of ITG GmbH generators required for routine doses preparation according to FDA recommendations.

Smoothened titania particles to improve radionuclide separation and their application to the development of a novel [68Ge]/[68Ga] generator

Smoothened titania particles for a long-lived radiopharmaceutical grade ⁶⁸Ge/⁶⁸Ga generator.

68Ga-DOTA and analogs: Current status and future perspectives

The construction of the ⁶⁸Ge/⁶⁸Ga generator has increased application of radiopharmaceuticals labeled with this isotope in medicine. ⁶⁸Ga-PET is widely employed in the management of neuroendocrine tumors but favorable chemistry with tri- and tetraaza-ring molecules has opened wide range of ⁶⁸Ga application in other fields of PET imaging. This review covers the radiopharmaceuticals labeled with gallium in molecular imaging and shows perspectives on the use of gallium-68 as a substitute for technetium-99, fluorine-18 and carbon-11 in some applications.

Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathways

Abstract Early and specific tumor detection and also therapy selection and response evaluation are some challenges of personalized medicine. This calls for high sensitive and specific molecular imaging such as positron emission tomography (PET). The use of peptides for PET molecular imaging has undeniable advantages: possibility of targeting through peptide-receptor interaction, small size and low-molecular weight conferring good penetration in the tissue or at cellular level, low toxicity, no antigenicity, and possibility of wide choice for radiolabeling. Among β(+)-emitter radioelements, Gallium-68 is a very attractive positron-emitter compared with carbon-11 or fluorine-18 taking into account its easy production via a (68)Ge/(68)Ga generator and well established radiochemistry. Gallium-68 chemistry is based on well-defined coordination complexes with macrocycle or chelates having strong binding properties, particularly suitable for linking peptides that allow resistance to in vivo transchelation of the metal ion. Understanding specific and nonspecific molecular mechanisms involved in oncogenesis is one major key to develop new molecular imaging tools. The present review focuses on peptide signaling involved in different oncogenic pathways. This peptide signalization might be common for tumoral and non-tumoral processes or could be specific of an oncological process. This review describes gallium chemistry and different (68)Ga-radiolabeled peptides already in use or under development aiming at developing molecular PET imaging of different oncological processes.

Preparation and evaluation of SnO2-based 68Ge/68Ga generator made from 68Ge produced through (nat)Zn(α,xn) reaction

(68)Ge was produced by (nat)Zn(α,xn)(68)Ge reaction and its production yield was 31.82 kBq/μAh (0.86 μCi/μAh) at the end of irradiation (EOI). A simple chromatographic method using a SnO2 column was employed to separate (68)Ge from the target material and the co-produced non-isotopic radioisotope impurities. (68)Ge retained in the column served as the (68)Ge/(68)Ga generator. Elution efficiency of the column was about 60%. First 2 ml of the eluate contained more than 95% of the elutable activity. Post-elution purification cum concentration was done with a small cation exchange resin column. The presence of the inactive tin ions in the (68)Ga eluate was determined by the ICP-OES technique and was found to be about 0.03 ppm. Radiochemical purity of the final (68)Ga preparation was more than 99.99% and it was found to be suitable for making complex with ethylenediamine-N,N,N',N'-tetrakis(methylene phosphonic acid) (EDTMP).

An Increasing Role for 68Ga PET Imaging: A Perspective on the Availability of Parent 68Ge Material for Generator Manufacturing in an Expanding Market

The use of gallium-68 for molecular imaging is gaining momentum world-wide. While our understanding of 68Ga chemistry, generators, and associated synthesis modules appear to have advanced to a clinically-reliable stage, uncertainty in the supply of radiopharmaceutically-suitable parent is of significant concern. In this work, we examine the current supply of 68Ge in an effort to better understand the potential for expansion of manufacturing to meet an increasing demand for 68Ga. Although specific information on sales and demand of 68Ge is highly business sensitive and thus guarded, our examination finds no shortage in the current supply of 68Ge. On the other hand, increases in the use of 68Ge generators for clinical applications in the United States point to the need for continued support for production at DOE laboratories in the United States to ensure a reliable supply and suggests that new commercial facilities may be needed to meet the increasing demand.

How to cite this article

Schultz MK, Donahue P, Musgrave NI, Zhernosekov K, Naidoo C, Razbash A, Tworovska I, Dick DW, Watkins GL, Graham MM, Runde W, Clanton JA, Sunderland JJ. An Increasing Role for 68Ga PET Imaging: A Perspective on the Availability of Parent 68Ge Material for Generator Manufacturing in an Expanding Market. J Postgrad Med Edu Res 2013;47(1):26-30.

Microbial challenge tests on nonradioactive TiO2-based 68Ge/68Ga generator columns

OBJECTIVES

The aim of this study was to test the survival of microorganisms in eluents used for (68)Ge/(68)Ga generators and for regeneration of nonradioactive (68)Ge/(68)Ga generator columns after high microbial load. Nonradioactive generator columns were loaded with various microorganisms and tested to determine whether the microorganisms were proliferating or surviving in eluates of the columns.

MATERIALS AND METHODS

TiO(2) columns used in a commercially available (68)Ge/(68)Ga generators for absorption of (68)Ge were loaded with greater than 10(7) colony-forming units (CFU) of Staphylococcus aureus, Clostridium sporogenes, Candida albicans, Helicobacter pylori, Aspergillus niger and Deinococcus radiodurans. Columns were eluted with 0.1 N HCl under standard eluting conditions. Elutions, over a prolonged time period, were tested for endotoxins, sterility and number of CFU.

RESULTS

Initial tests on the eluent (0.1 N HCl) already showed limited survival of microorganisms. Using TiO(2) generator columns, even with a higher load of microorganisms no survival of any microorganism could be detected in subsequent elutions, neither in colony-forming unit assays nor in sterility testing. In addition, endotoxin tests showed no elevated levels in any of the eluent samples, even days after incubation.

CONCLUSION

The conditions used in this type of (68)Ge/(68)Ga generator are highly unfavourable for survival or growth of microorganisms. The risks associated with incidental microbial contaminations during the lifetime of such a generator are therefore very low.

Long-term evaluation of TiO2-based 68Ge/68Ga generators and optimized automation of [68Ga]DOTATOC radiosynthesis

Interest in using (68)Ga is rapidly increasing for clinical PET applications due to its favorable imaging characteristics and increased accessibility. The focus of this study was to provide our long-term evaluations of the two TiO(2)-based (68)Ge/(68)Ga generators and develop an optimized automation strategy to synthesize [(68)Ga]DOTATOC by using HEPES as a buffer system. This data will be useful in standardizing the evaluation of (68)Ge/(68)Ga generators and automation strategies to comply with regulatory issues for clinical use.

(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives

In this review we give an overview of current knowledge of (68)Ga-labeled pharmaceuticals, with focus on imaging receptor-mediated processes. A major advantage of a (68)Ge/(68)Ga generator is its continuous source of (68)Ga, independently from an on-site cyclotron. The increase in knowledge of purification and concentration of the eluate and the complex ligand chemistry has led to (68)Ga-labeled pharmaceuticals with major clinical impact. (68)Ga-labeled pharmaceuticals have the potential to cover all today's clinical options with (99m)Tc, with the concordant higher resolution of positron emission tomography (PET) in comparison with single photon emission computed tomography. (68)Ga-labeled analogs of octreotide, such as DOTATOC, DOTANOC, and DOTA-TATE, are in clinical application in nuclear medicine, and these analogs are now the most frequently applied of all (68)Ga-labeled pharmaceuticals. All the above-mentioned items in favor of successful application of (68)Ga-labeled radiopharmaceuticals for imaging in patients are strong arguments for the development of a (68)Ge/(68)Ga generator with Marketing Authorization and thus to provide pharmaceutical grade eluate. Moreover, now not one United States Food and Drug Administration-approved or European Medicines Agency-approved (68)Ga-radiopharmaceutical is available. As soon as these are achieved, a whole new radiopharmacy providing PET radiopharmaceuticals might develop.

Nanoceria-PAN composite-based advanced sorbent material: a major step forward in the field of clinical-grade 68Ge/68Ga generator

The (68)Ge/(68)Ga generator has high potential for clinical positron emission tomography (PET) imaging. However, because of the unavailability of a suitable sorbent material, the commercially available (68)Ge/(68)Ga generators are not directly adaptable for the preparation of (68)Ga-labeled radiopharmaceuticals. In view of this, a new nanoceria-polyacrylonitrile (PAN) composite sorbent has been synthesized by decomposition of a cerium oxalate precursor to cerium oxide and its subsequent incorporation in PAN matrix for the development of a clinical grade (68)Ge/(68)Ga generator. The X-ray diffraction (XRD) studies and BET nitrogen adsorption technique revealed that nanocrystalline ceria had an average particle size of approximately 10 nm, surface area of 72 +/- 3 m(2)/g and an average pore size of 3.8 +/- 0.1 A. Investigation of the distribution ratio (K(d)) values for the prepared sorbent in 0.01 N HCl medium revealed the suitability of the sorbent for the quantitative retention of (68)Ge and efficient elution of clinical grade (68)Ga. A 370 MBq (10 mCi) (68)Ge/(68)Ga chromatographic generator was developed using this sorbent. (68)Ga could be regularly eluted from this generator with >80% elution yield. The eluted (68)Ga possess high radionuclidic purity (<1 x 10(-5)% of (68)Ge impurity), chemical purity (<0.1 ppm of Ce, Fe and Mn ions) and was amenable for the preparation of (68)Ga-labeled radiopharmaceuticals. The generator gave a consistent performance with respect to the elution yield and purity of (68)Ga over an extended period of 7 months.

A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent

The development of new myocardial perfusion imaging agents for positron emission tomography (PET) may improve the resolution and quantitation of changes in regional myocardial perfusion measurement. It is known that a (68)Ge/(68)Ga generator can provide a convenient source of PET tracers because of the long physical half-life of (68)Ge (271 days). A new ligand, 7,8-dithia-16,24-diaza-trispiro[5.2.5.2.5.3]pentacosa-15,24-diene, which consists of a N(2)S(2)-chelating core incorporated into three cyclohexyl rings, was prepared. To test feasibility and potential utility, the N(2)S(2) ligand was successfully labeled and tested with (67)Ga (half-life=3.26 day; gamma=93.3, 184.6 and 300.2 keV), which showed >92% radiochemical purity. The corresponding "cold" Ga complex was synthesized, and its structure containing a pyramidal N(2)S(2) chloride core was elucidated with X-ray crystallography. In vivo biodistribution of this novel (67)Ga complex, evaluated in normal rats, exhibited excellent heart uptake and retention, with 2.1% and 0.9% initial dose/organ at 2 and 60 min, respectively, after an intravenous injection. Autoradiography was performed in normal rats and in rats that had the left anterior descending coronary artery permanently ligated surgically. Autoradiography showed an even uptake of activity in the normal heart, and there was a distinctively lower uptake in the damaged side of the surgically modified heart. In conclusion, the new N(2)S(2) ligand was readily prepared and labeled with radioactive (67)Ga. Biodistribution in rats revealed high initial heart uptake and relatively high retention reflecting regional myocardial perfusion.